|
Canada-SK-MOSSBANK Azienda Directories
|
Azienda News:
- Acquired Hemophilia Treatment Management - Medscape
Recombinant antihemophilic factor, porcine sequence Historically, porcine factor VIII has provided a good effect A porcine sequence recombinant FVIII (rpFVIII; Obizur) was approved by the US Food and Drug Administration (FDA) in 2014 for treatment of bleeding episodes in adults with acquired hemophilia
- Hemophilia Therapies - Rare Disease Advisor
Koāte ® (antihemophilic factor [human]), also known as Koāte-DVI, is a human plasma-derived FVIII indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A Initially approved in the US in 1974, the processing methods have been updated over the years to make the product safer from viral contamination
- Acquired hemophilia A (and other acquired coagulation factor . . .
Acquired clotting factor inhibitors are autoantibodies that either inhibit the activity or increase the clearance of a clotting factor These patients often present with unexplained bleeding and prolonged clotting times Inhibitors in individuals with congenital hemophilia A and B are due to alloantibodies against infused factor concentrates
- Treatment Options in Hemophilia - PMC
Unlike the treatment options described so far, gene therapy for hemophilia offers the prospect of the longest-lasting possible increase in factor levels, rising to normal levels This would be achieved after a single infusion of a recombinant, adeno-associated virus (AAV)–based vector containing the gene for the missing coagulation factor
|
|